Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
Public ClinicalTrials.gov record NCT02513472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, single-arm, multicenter, Phase 1b/2 study of eribulin mesylate in combination with pembrolizumab in participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
Study identification
- NCT ID
- NCT02513472
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 258 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 27, 2015
- Primary completion
- Jul 30, 2019
- Completion
- Apr 5, 2021
- Last update posted
- May 4, 2022
2015 – 2021
United States locations
- U.S. sites
- 22
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Facility #1 | Duarte | California | 91010 | — |
| Facility #1 | Santa Barbara | California | 93105 | — |
| Facility #1 | Denver | Colorado | 80218 | — |
| Facility #1 | Miami | Florida | 33176 | — |
| Facility #1 | West Palm Beach | Florida | 33401 | — |
| Facility #1 | Boston | Massachusetts | 02115 | — |
| Facility #2 | Boston | Massachusetts | 02115 | — |
| Facility #1 | Minneapolis | Minnesota | 55407 | — |
| Facility #1 | St Louis | Missouri | 63110 | — |
| Facility #1 | Lebanon | New Hampshire | 03756 | — |
| Facility #1 | New York | New York | 10032 | — |
| Facility #2 | New York | New York | 10065 | — |
| Facility #1 | Chattanooga | Tennessee | 37404 | — |
| Facility #1 | Nashville | Tennessee | 37203 | — |
| Facility #1 | Austin | Texas | 78731 | — |
| Facility #1 | Fort Worth | Texas | 76104 | — |
| Facility #1 | San Antonio | Texas | 78217 | — |
| Facility #2 | San Antonio | Texas | 78229 | — |
| Facility #1 | Sherman | Texas | 75090 | — |
| Facility #1 | Salem | Virginia | 24153 | — |
| Facility #1 | Winchester | Virginia | 22601 | — |
| Facility #1 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02513472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2022 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02513472 live on ClinicalTrials.gov.